Study of the fetal and maternal microbiota in pregnant women with intrauterine growth restriction and its relationship with inflammatory biomarkers A case-control study protocol (SPIRIT compliant)
Por:
Fernandez-Gonzalez S, Ortiz-Arrabal O, Joan Galiot Torrecillas EIX Solucions gràfiques, Pérez-Cruz M, Chueca N, Gómez-Roig MD and Gómez-Llorente C
Publicada:
13 nov 2020
Categoría:
Medicine (miscellaneous)
Resumen:
In general terms, fetal growth restriction (FGR) is considered the impossibility of achieving the genetically determined potential size. In the vast majority of cases, it is related to uteroplacental insufficiency. Although its origin remains unknown and causes are only known in 30% of cases, it is believed to be related to an interaction of environmental and genetic factors with either a fetal or maternal origin. One hypothesis is that alterations in the gastrointestinal microbiota composition, and thus alteration in the immune response, could play a role in FGR development. We performed an observational, prospective study in a subpopulation affected with FGR to elucidate the implications of this microbiota on the FGR condition. A total of 63 fetuses with FGR diagnosed in the third trimester as defined by the Delphi consensus, and 63 fetuses with fetal growth appropriate for gestational age will be recruited. Obstetric and nutritional information will be registered by means of specific questionnaires. We will collect maternal fecal samples between 30 to 36 weeks, intrapartum samples (maternal feces, maternal and cord blood) and postpartum samples (meconium and new-born feces at 6 weeks of life). Samples will be analyzed in the Department of Biochemistry and Molecular Biology II, Nutrition and Food Technology Institute of the University of Granada (UGR), for the determination of the gastrointestinal microbiota composition and its relationship with inflammatory biomarkers. This study will contribute to a better understanding of the influence of gastrointestinal microbiota and related inflammatory biomarkers in the development of FGR. Trial registration: NCT04047966. Registered August 7, 2019, during the recruitment stage. Retrospectively registered. Ongoing research.
Filiaciones:
Fernandez-Gonzalez S:
Hospital de Sant Joan de Déu. D'Esplugues de Llobregat, Passeig Sant Joan de Déu 2. Esplugues, Barcelona
Ortiz-Arrabal O:
Biochemistry and Molecular Biology II Department, School of Pharmacy, University of Granada, Campus de Cartuja s/n
Joan Galiot Torrecillas EIX Solucions gràfiques:
Hospital de Sant Joan de Déu. D'Esplugues de Llobregat, Passeig Sant Joan de Déu 2. Esplugues, Barcelona
Pérez-Cruz M:
Hospital de Sant Joan de Déu. D'Esplugues de Llobregat, Passeig Sant Joan de Déu 2. Esplugues, Barcelona
Chueca N:
Department of Microbiology, University Hospital Campus de la Salud
Instituto de Investigación Biosanitaria ibs. GRANADA
Gómez-Roig MD:
Hospital de Sant Joan de Déu. D'Esplugues de Llobregat, Passeig Sant Joan de Déu 2. Esplugues, Barcelona
Gómez-Llorente C:
Biochemistry and Molecular Biology II Department, School of Pharmacy, University of Granada, Campus de Cartuja s/n
Institute of Nutrition and Food Technology "Jose Mataix", Center of Biomedical Research, University of Granada, Granada
CIBEROBN (CIBER Physiopathology of Obesity and Nutrition), Instituto de Salud Carlos III, Madrid, Spain
Green Published, Green Submitted, gold
|